SIOX
Price:
$0.415
Market Cap:
$30.70M
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.[Read more]
Industry
Biotechnology
IPO Date
2015-06-11
Stock Exchange
NASDAQ
Ticker
SIOX
According to Sio Gene Therapies Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.06. This represents a change of -26.73% compared to the average of -1.45 of the last 4 quarters.
The mean historical PE Ratio of Sio Gene Therapies Inc. over the last ten years is -2.99. The current -1.06 PE Ratio has changed 3.44% with respect to the historical average. Over the past ten years (40 quarters), SIOX's PE Ratio was at its highest in in the June 2022 quarter at -0.79. The PE Ratio was at its lowest in in the September 2015 quarter at -26.55.
Average
-2.99
Median
-1.05
Minimum
-8.19
Maximum
0
Discovering the peaks and valleys of Sio Gene Therapies Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 403.87%
Maximum Annual PE Ratio = 0
Minimum Annual Increase = -Infinity%
Minimum Annual PE Ratio = -8.19
Year | PE Ratio | Change |
---|---|---|
2022 | -0.68 | -83.75% |
2021 | -4.20 | 403.87% |
2020 | -0.83 | -33.71% |
2019 | -1.26 | 95.10% |
2018 | -0.64 | -92.13% |
2017 | -8.19 | 0.52% |
2016 | -8.14 | -Infinity% |
The current PE Ratio of Sio Gene Therapies Inc. (SIOX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.91
5-year avg
-1.52
10-year avg
-2.99
Sio Gene Therapies Inc.’s PE Ratio is less than Magenta Therapeutics, Inc. (-0.04), less than TRACON Pharmaceuticals, Inc. (0), less than ARCA biopharma, Inc. (0.02), greater than Neoleukin Therapeutics, Inc. (-58.03), less than CytomX Therapeutics, Inc. (-0.98), less than Assembly Biosciences, Inc. (7.73), greater than Instil Bio, Inc. (-2.10), greater than Nuvation Bio Inc. (-1.50), greater than Rezolute, Inc. (-1.10), greater than XOMA Corporation (-4.04), greater than Vincerx Pharma, Inc. (-19.71), less than Protara Therapeutics, Inc. (-0.47), greater than Vaccinex, Inc. (-1.35), less than Monopar Therapeutics Inc. (-0.33), greater than Miromatrix Medical Inc. (-8.34), greater than Surrozen, Inc. (-3.41), less than Tempest Therapeutics, Inc. (-0.70), less than SAB Biotherapeutics, Inc. (-0.67), less than Aligos Therapeutics, Inc. (-0.93), less than Molecular Partners AG (-0.78), greater than null (-3.01),
Company | PE Ratio | Market cap |
---|---|---|
-0.04 | $42.44M | |
0 | $136.30K | |
0.02 | $34.82M | |
-58.03 | $8.20M | |
-0.98 | $78.90M | |
7.73 | $107.75M | |
-2.10 | $179.70M | |
-1.50 | $764.36M | |
-1.10 | $304.25M | |
-4.04 | $361.20M | |
-19.71 | $11.06M | |
-0.47 | $53.43M | |
-1.35 | $9.06M | |
-0.33 | $87.22M | |
-8.34 | $92.95M | |
-3.41 | $38.09M | |
-0.70 | $25.00M | |
-0.67 | $37.29M | |
-0.93 | $58.44M | |
-0.78 | $247.30M | |
-3.01 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Sio Gene Therapies Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Sio Gene Therapies Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Sio Gene Therapies Inc.'s PE Ratio?
How is the PE Ratio calculated for Sio Gene Therapies Inc. (SIOX)?
What is the highest PE Ratio for Sio Gene Therapies Inc. (SIOX)?
What is the 3-year average PE Ratio for Sio Gene Therapies Inc. (SIOX)?
What is the 5-year average PE Ratio for Sio Gene Therapies Inc. (SIOX)?
How does the current PE Ratio for Sio Gene Therapies Inc. (SIOX) compare to its historical average?